The Hematopoiesis and Hematological Malignancies (HHM) Program is an integrated and collaborative program with 28 members from 3 Departments. Program members are supported by $ 4,515,551 in peer reviewed funding (direct costs), with $ 1,113,418 from the NCI. Program members have a total of 292 peer-reviewed publications, including 21% intraprogrammatic and 13% interprogrammatic publications. The overall goals of the HHM Program are: 1) to foster scientific interactions among investigators involved in clinical management and biological studies of hematological malignancies;2) to promote translational research and facilitate the transfer of laboratory research to the management of patients with these diseases;and 3) to promote optimal use of resources within the University of Chicago Comprehensive Cancer Center and collaborating departments. Cytogenetic and molecular analyses of hematological malignancies have led to the identification of many genes that are involved in normal hematopoiesis, as well as in the pathogenesis of leukemia, lymphoma, myeloproliferative disorders, and multiple myeloma. These insights have refined diagnostic and prognostic capabilities, and have provided the foundation for risk-adapted, molecularly targeted therapeutics. Members of this Program have had major roles in defining the pathogenetic events leading to the development of hematological malignancies. These important insights have begun to be translated into novel molecularly targeted treatment approaches. The HHM Program is comprised of a tightly integrated group of investigators who are linked by common research themes and are working towards achievement of common goals. Specifically, the three primary research themes of the investigators in the HHM Program are: 1) to investigate mechanisms of normal and malignant hematopothesis by analyzing the molecular genetics of normal hematopothesis and the development of malignant diseases;2) to generate and analyze model systems to dissect the functions of genes that are critical to normal hematopoiesis and to the development of hematopoietic diseases;and 3) to translate these insights into the design and conduct of novel risk-adapted clinical trials in hematological malignancies.
The HHM Program consists of an interactive group of investigators involved in basic, clinical, and translational research. The Program's research is focused on normal blood cell development, mechanisms of transformation of hematopoietic cells into hematologic cancers, and the development of therapies that target pathways that become disrupted by mutations in genes that are critical to normal hematopoietic development. This approach will facilitate progress in the design and implementation of clinical therapeutic strategies for patients with cancers affecting the hematopoietic system.
|Feng, Christine H; Gerry, Emily; Chmura, Steven J et al. (2015) An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91:58-64|
|Ming, Mei; Zhao, Baozhong; Shea, Christopher R et al. (2015) Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135:936-45.e4|
|Ming, Mei; Zhao, Baozhong; Qiang, Lei et al. (2015) Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 91:242-7|
|Shah, Palak; He, Yu-Ying (2015) Molecular regulation of UV-induced DNA repair. Photochem Photobiol 91:254-64|
|Ming, Mei; Han, Weinong; Zhao, Baozhong et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33|
|Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32|
|Rudra, Sonali; Al-Hallaq, Hania A; Feng, Christine et al. (2014) Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15:4547|
|Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420|
|Stumpf, Melanie; Zhou, Xuyu; Chikuma, Shunsuke et al. (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44:1737-46|
|Geeleher, Paul; Cox, Nancy J; Huang, R Stephanie (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47|
Showing the most recent 10 out of 354 publications